1. Home
  2. CHN vs CTNM Comparison

CHN vs CTNM Comparison

Compare CHN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHN
  • CTNM
  • Stock Information
  • Founded
  • CHN 1992
  • CTNM 2009
  • Country
  • CHN United States
  • CTNM United States
  • Employees
  • CHN N/A
  • CTNM N/A
  • Industry
  • CHN Investment Managers
  • CTNM
  • Sector
  • CHN Finance
  • CTNM
  • Exchange
  • CHN Nasdaq
  • CTNM Nasdaq
  • Market Cap
  • CHN 128.4M
  • CTNM 122.9M
  • IPO Year
  • CHN N/A
  • CTNM 2024
  • Fundamental
  • Price
  • CHN $13.07
  • CTNM $4.76
  • Analyst Decision
  • CHN
  • CTNM Strong Buy
  • Analyst Count
  • CHN 0
  • CTNM 4
  • Target Price
  • CHN N/A
  • CTNM $22.50
  • AVG Volume (30 Days)
  • CHN 31.8K
  • CTNM 119.1K
  • Earning Date
  • CHN 01-01-0001
  • CTNM 08-12-2025
  • Dividend Yield
  • CHN 0.19%
  • CTNM N/A
  • EPS Growth
  • CHN N/A
  • CTNM N/A
  • EPS
  • CHN N/A
  • CTNM N/A
  • Revenue
  • CHN N/A
  • CTNM N/A
  • Revenue This Year
  • CHN N/A
  • CTNM N/A
  • Revenue Next Year
  • CHN N/A
  • CTNM N/A
  • P/E Ratio
  • CHN N/A
  • CTNM N/A
  • Revenue Growth
  • CHN N/A
  • CTNM N/A
  • 52 Week Low
  • CHN $9.00
  • CTNM $3.35
  • 52 Week High
  • CHN $12.98
  • CTNM $22.00
  • Technical
  • Relative Strength Index (RSI)
  • CHN 58.19
  • CTNM N/A
  • Support Level
  • CHN $13.13
  • CTNM N/A
  • Resistance Level
  • CHN $13.33
  • CTNM N/A
  • Average True Range (ATR)
  • CHN 0.17
  • CTNM 0.00
  • MACD
  • CHN 0.01
  • CTNM 0.00
  • Stochastic Oscillator
  • CHN 75.70
  • CTNM 0.00

About CHN China Fund Inc. (The)

CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: